Enhancer-driven transcription of MCM8 by E2F4 promotes ATR pathway activation and glioma stem cell characteristics
暂无分享,去创建一个
Ji-peng Yang | Guo-Zhu Sun | Chen Li | Jian Song | Song Yang | Haijun Shi | Yin-long Zhao | Hong-jiang Liu | Jian-kai Yang | Yu-meng Sun | Yi-meng Zhang | Hong-lei Liu
[1] He Fei,et al. High Expression of E2F4 Is an Adverse Prognostic Factor and Related to Immune Infiltration in Oral Squamous Cell Carcinoma , 2022, BioMed research international.
[2] Shu Yang,et al. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma , 2022, Frontiers in Oncology.
[3] Zhixiong Liu,et al. Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment , 2022, CNS neuroscience & therapeutics.
[4] Feng Xu,et al. DNA damage-induced translocation of mitochondrial factor HIGD1A into the nucleus regulates homologous recombination and radio/chemo-sensitivity , 2022, Oncogene.
[5] Xiaosong Hu,et al. ACTL6A deficiency induces apoptosis through impairing DNA replication and inhibiting the ATR-Chk1 signaling in glioblastoma cells. , 2022, Biochemical and biophysical research communications.
[6] Hongjin Shao,et al. E2F4-induced AGAP2-AS1 up-regulation accelerates the progression of colorectal cancer via miR-182-5p/CFL1 axis , 2021, Digestive and Liver Disease.
[7] Xueran Chen,et al. Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation , 2021, Oncogenesis.
[8] M. Eskandani,et al. Recent advances in γH2AX biomarker-based genotoxicity assays: A marker of DNA damage and repair. , 2021, DNA repair.
[9] Pei-Li Yao,et al. Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma , 2021, Oncology reports.
[10] X. Cai,et al. E2F4 Promotes the Proliferation of Hepatocellular Carcinoma Cells through Upregulation of CDCA3 , 2021, Journal of Cancer.
[11] Yang Jiang,et al. MCM8 is regulated by EGFR signaling and promotes the growth of glioma stem cells through its interaction with DNA-replication-initiating factors , 2021, Oncogene.
[12] H. Cui,et al. Competing Endogenous RNA Networks in Glioma , 2021, Frontiers in Genetics.
[13] Jun Li,et al. Knockdown of MCM8 functions as a strategy to inhibit the development and progression of osteosarcoma through regulating CTGF , 2021, Cell Death & Disease.
[14] Chaojie Wang,et al. Long noncoding RNA SNHG9 facilitates growth of glioma stem‐like cells via miR‐326/SOX9 axis , 2021, The journal of gene medicine.
[15] José A. Guerrero-Martínez,et al. TGFβ promotes widespread enhancer chromatin opening and operates on genomic regulatory domains , 2020, Nature Communications.
[16] C. P. K. Patro,et al. A functional variant on 20q13.33 related to glioma risk alters enhancer activity and modulates expression of multiple genes , 2020, Human mutation.
[17] Jiumao Lin,et al. Identification of mini‐chromosome maintenance 8 as a potential prognostic marker and its effects on proliferation and apoptosis in gastric cancer , 2020, Journal of cellular and molecular medicine.
[18] H. Saya,et al. Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma , 2020, Scientific Reports.
[19] C. Kramm,et al. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells , 2020, Cell Death & Disease.
[20] N. Curtin,et al. DNA damage checkpoint kinases in cancer , 2020, Expert Reviews in Molecular Medicine.
[21] H. Cui,et al. NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR , 2020, Signal Transduction and Targeted Therapy.
[22] J. Lukas,et al. Physiological Tolerance to ssDNA Enables Strand Uncoupling during DNA Replication. , 2020, Cell reports.
[23] Yan Du,et al. E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2 , 2020, Journal of cellular and molecular medicine.
[24] Huirong Shi,et al. ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer , 2020, Therapeutic advances in medical oncology.
[25] Y. Drew,et al. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations? , 2019, Pharmacology & therapeutics.
[26] J. Komorowski,et al. Mapping chromatin accessibility and active regulatory elements reveals pathological mechanisms in human gliomas , 2019, Nature Communications.
[27] Monica Stanciu,et al. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma , 2019, Nature Communications.
[28] A. Dubrovska,et al. Cancer Stem Cells and Radioresistance: DNA Repair and Beyond , 2019, Cancers.
[29] Atique U. Ahmed,et al. Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma , 2018, Cell Death and Disease.
[30] A. LeBeau,et al. The role of CD133 in cancer: a concise review , 2018, Clinical and Translational Medicine.
[31] J. Sarkaria,et al. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers , 2018, eLife.
[32] E. Lecona,et al. Targeting ATR in cancer , 2018, Nature Reviews Cancer.
[33] J. Sarkaria,et al. Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues , 2018, Genome Biology.
[34] T. Ochiya,et al. Drug Resistance Driven by Cancer Stem Cells and Their Niche , 2017, International journal of molecular sciences.
[35] N. Oleinick,et al. ATR/CHK1 inhibitors and cancer therapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[36] H. Clevers,et al. Cancer stem cells revisited , 2017, Nature Medicine.
[37] R. Benhida,et al. ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. , 2017, MedChemComm.
[38] J. Wysocka,et al. Ever-Changing Landscapes: Transcriptional Enhancers in Development and Evolution , 2016, Cell.
[39] J. Parker,et al. ATR maintains chromosomal integrity during postnatal cerebellar neurogenesis and is required for medulloblastoma formation , 2016, Development.
[40] L. J. Lee,et al. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. , 2016, Cancer cell.
[41] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[42] F. Gage,et al. Enhancer Divergence and cis-Regulatory Evolution in the Human and Chimp Neural Crest , 2015, Cell.
[43] A. Ryan,et al. ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.
[44] C. Glass,et al. The selection and function of cell type-specific enhancers , 2015, Nature Reviews Molecular Cell Biology.
[45] Yuanyi Feng,et al. The scaffold protein Nde1 safeguards the brain genome during S phase of early neural progenitor differentiation , 2014, eLife.
[46] R. Muschel,et al. Targeting ATR in DNA damage response and cancer therapeutics. , 2014, Cancer treatment reviews.
[47] J. Wysocka,et al. Modification of enhancer chromatin: what, how, and why? , 2013, Molecular cell.
[48] Y. Mao,et al. B7-H4 expression is elevated in human U251 glioma stem-like cells and is inducible in monocytes cultured with U251 stem-like cell conditioned medium , 2013, Chinese journal of cancer.
[49] E. Furlong,et al. Transcription factors: from enhancer binding to developmental control , 2012, Nature Reviews Genetics.
[50] L. Truong,et al. Dbf4 Is Direct Downstream Target of Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3-related (ATR) Protein to Regulate Intra-S-phase Checkpoint* , 2011, The Journal of Biological Chemistry.
[51] M. Hidalgo,et al. Inhibition of Ataxia Telangiectasia‐ and Rad3 ‐Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor‐Initiating Cell Fraction , 2011, Stem cells.
[52] Dustin E. Schones,et al. High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.
[53] Angelo L. Vescovi,et al. Brain tumour stem cells , 2006, Nature Reviews Cancer.
[54] O. Cuvier,et al. MCM8 Is an MCM2-7-Related Protein that Functions as a DNA Helicase during Replication Elongation and Not Initiation , 2005, Cell.
[55] Kai Rothkamm,et al. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[56] Shota Katayama,et al. Isolation and characterization of cancer stem cells derived from human glioblastoma. , 2021, American journal of cancer research.
[57] P. Godoy,et al. E2F transcription factors associated with up-regulated genes in glioblastoma. , 2017, Cancer biomarkers : section A of Disease markers.
[58] R. Schneider,et al. Lateral Thinking: How Histone Modifications Regulate Gene Expression. , 2016, Trends in genetics : TIG.
[59] W. Weiss,et al. Glial progenitors as targets for transformation in glioma. , 2014, Advances in cancer research.
[60] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..